162 related articles for article (PubMed ID: 8630274)
1. Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Br J Cancer; 1996 May; 73(10):1171-7. PubMed ID: 8630274
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
4. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
5. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
7. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
8. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
9. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
10. A human neuroblastoma xenograft model for 125-I-metaiodobenzylguanidine biodistribution studies.
Lavitrano M; Servidei T; Mastrangelo S; Tornesello A; Fioretti D; Di Stefano C; Riccardi A; Franceschini R; Riccardi R
J Neurooncol; 1997 Jan; 31(1-2):159-64. PubMed ID: 9049844
[TBL] [Abstract][Full Text] [Related]
11. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
12. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
13. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
15. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells.
Smets LA; Janssen M; Rutgers M; Ritzen K; Buttenhuis C
Int J Cancer; 1991 Jun; 48(4):609-15. PubMed ID: 2045205
[TBL] [Abstract][Full Text] [Related]
17. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
Vaidyanathan G; Strickland DK; Zalutsky MR
Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
[TBL] [Abstract][Full Text] [Related]
18. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.
Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 1995 Jan; 22(1):61-4. PubMed ID: 7735171
[TBL] [Abstract][Full Text] [Related]
19. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
20. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.
Buck J; Bruchelt G; Girgert R; Treuner J; Niethammer D
Cancer Res; 1985 Dec; 45(12 Pt 1):6366-70. PubMed ID: 3864530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
